Drug firm Nectar Lifesciences today said its standalone net profit rose by 19.53% to Rs 31.82 crore for the quarter ended March 31, 2011.
The company had posted a standalone net profit of Rs 26.62 crore in the corresponding period previous fiscal, Nectar Lifesciences said in a filing to the Bombay Stock Exchange (BSE).
Net sales of the company for the fourth quarter ended March 31, 2011 stood at Rs 338.81 crore as compared to Rs 241.66 crore for the same period last fiscal.
Standalone net profit of the company for the financial year ended March 31, 2011 stood at Rs 101.87 crore as compared to Rs 91.97 crore in the previous fiscal.
The company posted net sales of Rs 1056.22 crore for the year ended March 31, 2011 as compared to Rs 845.79 crore for the financial year ended March 31, 2010.
Shares of Nectar Lifesciences today closed at Rs 27.05 on the BSE, up 2.08% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app